Earnings Feed
Start Free
Aptose Biosciences Inc.·4

Jul 1, 5:03 PM ET

Vincent Mark D. 4

4 · Aptose Biosciences Inc. · Filed Jul 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Aptose (APTO) Former Director Mark D. Vincent Sells 522,347 Shares

What Happened

  • Mark D. Vincent, a former director of Aptose Biosciences (APTO), reported multiple dispositions in June 2026. He sold 14 shares on 2026-06-13 at US$1.72 ($24) and disposed of a combined ~522,333 additional shares on 2026-06-30 reported as derivative dispositions (multiple line items). Although many 6/30 entries show $0.00 (derivative reporting), the filing notes these were disposed pursuant to a board, shareholder and court-approved business arrangement under which a Hammi Pharmaceuticals subsidiary acquired all outstanding Aptose shares at C$2.41 per share (converted at C$1.40 = US$1.00), implying total consideration of roughly US$898,437 for the full block (all dates combined ≈ US$898,437).

Key Details

  • Transaction dates & prices:
    • 2026-06-13: 14 shares at US$1.72 (reported value US$24).
    • 2026-06-30: multiple derivative dispositions totaling ~522,333 shares; transaction price was C$2.41/share (F1), converted at C$1.40 = US$1.72/share (F2) though reported as $0.00 for derivative entries.
  • Shares disposed in total: ~522,347 (14 + ~522,333).
  • Shares owned after transaction: not specified in the provided filing.
  • Footnotes of note:
    • F1: Dispositions pursuant to a court-approved business arrangement; Hammi subsidiary acquired outstanding shares at C$2.41/share.
    • F2: Canadian-to-US conversion used C$1.40 = US$1.00.
    • F3 & remark: Some disposals involved options/derivatives with stated vesting schedules and subject to prior reverse-split adjustments.
  • Timeliness: Report filed 2026-07-01 for transactions through 2026-06-30 (appears timely).

Context

  • Many entries are listed as derivative dispositions — the filing indicates these were surrendered/converted as part of the acquisition rather than open-market sales. For retail investors, transactions tied to a take-private or acquisition process reflect the deal consideration rather than an independent insider sentiment signal. Options-related footnotes note vesting schedules and reverse-split adjustments; these are administrative details of the instruments involved, not separate market trades.

Insider Transaction Report

Form 4Exit
Period: 2026-06-30
Aptose Biosciences Inc.APTO
Vincent Mark D.
Other
Transactions
  • Disposition to Issuer

    Common Shares

    [F1][F2]
    2026-06-13$1.72/sh−14$24→ 0 total
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−3,333→ 0 total
    Exercise: $1.97Exp: 2034-02-05→ Common Shares (3,333 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−100,000→ 0 total
    Exercise: $0.66Exp: 2033-01-19→ Common Shares (100,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−50,000→ 0 total
    Exercise: $1.39Exp: 2032-01-17→ Common Shares (50,000 underlying)
  • Disposition to Issuer

    Director Option Grant

    [F1][F3]
    2026-06-30−50,000→ 0 total
    Exercise: $5.15Exp: 2030-03-11→ Common Shares (50,000 underlying)
  • Disposition to Issuer

    Director Option Grant

    [F1][F3]
    2026-06-30−154,000→ 0 total
    Exercise: $6.91Exp: 2030-01-30→ Common Shares (154,000 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    [F1][F3]
    2026-06-30−40,000→ 0 total
    Exercise: $1.91Exp: 2029-01-02→ Common Shares (40,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−10,000→ 0 total
    Exercise: $1.14Exp: 2027-03-28→ Common Shares (10,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−5,000→ 0 total
    Exercise: $1.03Exp: 2027-06-06→ Common Shares (5,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−60,000→ 0 total
    Exercise: $2.64Exp: 2028-01-19→ Common Shares (60,000 underlying)
  • Disposition to Issuer

    Director Stock Option (Right to Buy)

    [F1][F3]
    2026-06-30−50,000→ 0 total
    Exercise: $4.38Exp: 2031-01-04→ Common Shares (50,000 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
  • [F2]Converted from Canadian price of C$2.41 per share using exchange rate of C$1.4 = US$1.00.
  • [F3]Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
Signature
/s/ Mark D. Vincent|2026-07-01

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4